MX2021004860A - Piridazinas novedosas. - Google Patents
Piridazinas novedosas.Info
- Publication number
- MX2021004860A MX2021004860A MX2021004860A MX2021004860A MX2021004860A MX 2021004860 A MX2021004860 A MX 2021004860A MX 2021004860 A MX2021004860 A MX 2021004860A MX 2021004860 A MX2021004860 A MX 2021004860A MX 2021004860 A MX2021004860 A MX 2021004860A
- Authority
- MX
- Mexico
- Prior art keywords
- pyridazines
- novel
- novel pyridazines
- autotaxin
- therapy
- Prior art date
Links
- 150000004892 pyridazines Chemical class 0.000 title abstract 2
- 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 abstract 1
- 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a piridazinas novedosas, procesos para su preparación, composiciones farmacéuticas que las contienen y su uso en los tratamientos, en particular, en el tratamiento y/o la prevención de enfermedades y trastornos mediados por autotaxina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18203226 | 2018-10-29 | ||
| PCT/EP2019/079231 WO2020089098A1 (en) | 2018-10-29 | 2019-10-25 | Novel pyridazines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021004860A true MX2021004860A (es) | 2021-06-15 |
Family
ID=64048690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004860A MX2021004860A (es) | 2018-10-29 | 2019-10-25 | Piridazinas novedosas. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11104665B2 (es) |
| EP (1) | EP3873472B1 (es) |
| JP (1) | JP7214860B2 (es) |
| KR (1) | KR102823014B1 (es) |
| CN (1) | CN112996513B (es) |
| AR (1) | AR116877A1 (es) |
| AU (1) | AU2019373324B2 (es) |
| BR (1) | BR112021005445A2 (es) |
| CA (1) | CA3113712A1 (es) |
| CL (1) | CL2021000930A1 (es) |
| DK (1) | DK3873472T3 (es) |
| EA (1) | EA202191115A1 (es) |
| ES (1) | ES2955723T3 (es) |
| HU (1) | HUE063845T2 (es) |
| IL (1) | IL282425B2 (es) |
| MX (1) | MX2021004860A (es) |
| PH (1) | PH12021550903A1 (es) |
| PL (1) | PL3873472T3 (es) |
| TW (1) | TW202035374A (es) |
| WO (1) | WO2020089098A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11465982B2 (en) | 2019-07-22 | 2022-10-11 | Boehringer Ingelheim International Gmbh | Pyridazines |
| MX420421B (es) * | 2019-07-22 | 2025-02-10 | Boehringer Ingelheim Int | Derivados de n-(6-metoxi)pirizadin-3-il) amina, n-metilo como moduladores de autotaxina (atx) para el tratamiento de enfermedades inflamatorias de las vias respiratorias o fibroticas |
| US11485727B2 (en) * | 2019-07-22 | 2022-11-01 | Boehringer Ingelheim International Gmbh | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9273011B2 (en) * | 2011-10-28 | 2016-03-01 | Inhibitaxin Limited | Substituted pyridazines for the treatment of pain |
| SG11201507224RA (en) | 2013-03-14 | 2015-10-29 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| JP6435323B2 (ja) | 2013-06-19 | 2018-12-05 | ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． | 炎症性障害の治療のための新規化合物及びその医薬組成物 |
| US9604974B2 (en) * | 2015-01-22 | 2017-03-28 | University Of Mysore | Compounds as modulator of JAK-STAT pathway, methods and applications thereof |
| US11465982B2 (en) * | 2019-07-22 | 2022-10-11 | Boehringer Ingelheim International Gmbh | Pyridazines |
| MX420421B (es) * | 2019-07-22 | 2025-02-10 | Boehringer Ingelheim Int | Derivados de n-(6-metoxi)pirizadin-3-il) amina, n-metilo como moduladores de autotaxina (atx) para el tratamiento de enfermedades inflamatorias de las vias respiratorias o fibroticas |
| US11485727B2 (en) * | 2019-07-22 | 2022-11-01 | Boehringer Ingelheim International Gmbh | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators |
-
2019
- 2019-10-25 CN CN201980071245.4A patent/CN112996513B/zh active Active
- 2019-10-25 IL IL282425A patent/IL282425B2/en unknown
- 2019-10-25 KR KR1020217016497A patent/KR102823014B1/ko active Active
- 2019-10-25 JP JP2021523198A patent/JP7214860B2/ja active Active
- 2019-10-25 EA EA202191115A patent/EA202191115A1/ru unknown
- 2019-10-25 ES ES19801229T patent/ES2955723T3/es active Active
- 2019-10-25 AU AU2019373324A patent/AU2019373324B2/en active Active
- 2019-10-25 PL PL19801229.6T patent/PL3873472T3/pl unknown
- 2019-10-25 PH PH1/2021/550903A patent/PH12021550903A1/en unknown
- 2019-10-25 HU HUE19801229A patent/HUE063845T2/hu unknown
- 2019-10-25 MX MX2021004860A patent/MX2021004860A/es unknown
- 2019-10-25 WO PCT/EP2019/079231 patent/WO2020089098A1/en not_active Ceased
- 2019-10-25 EP EP19801229.6A patent/EP3873472B1/en active Active
- 2019-10-25 US US16/663,492 patent/US11104665B2/en active Active
- 2019-10-25 DK DK19801229.6T patent/DK3873472T3/da active
- 2019-10-25 CA CA3113712A patent/CA3113712A1/en active Pending
- 2019-10-25 BR BR112021005445-6A patent/BR112021005445A2/pt unknown
- 2019-10-28 TW TW108138765A patent/TW202035374A/zh unknown
- 2019-10-28 AR ARP190103115A patent/AR116877A1/es not_active Application Discontinuation
-
2021
- 2021-04-15 CL CL2021000930A patent/CL2021000930A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3873472A1 (en) | 2021-09-08 |
| IL282425B1 (en) | 2024-03-01 |
| KR20210084597A (ko) | 2021-07-07 |
| US20200131151A1 (en) | 2020-04-30 |
| CN112996513B (zh) | 2024-10-15 |
| WO2020089098A1 (en) | 2020-05-07 |
| CN112996513A (zh) | 2021-06-18 |
| AU2019373324A1 (en) | 2021-04-22 |
| TW202035374A (zh) | 2020-10-01 |
| EP3873472B1 (en) | 2023-07-12 |
| IL282425B2 (en) | 2024-07-01 |
| DK3873472T3 (da) | 2023-09-04 |
| PH12021550903A1 (en) | 2022-03-21 |
| AR116877A1 (es) | 2021-06-23 |
| HUE063845T2 (hu) | 2024-02-28 |
| IL282425A (en) | 2021-06-30 |
| JP2022506046A (ja) | 2022-01-17 |
| CL2021000930A1 (es) | 2021-11-12 |
| ES2955723T3 (es) | 2023-12-05 |
| JP7214860B2 (ja) | 2023-01-30 |
| US11104665B2 (en) | 2021-08-31 |
| AU2019373324B2 (en) | 2024-08-29 |
| PL3873472T3 (pl) | 2023-12-27 |
| BR112021005445A2 (pt) | 2021-06-15 |
| KR102823014B1 (ko) | 2025-06-20 |
| EA202191115A1 (ru) | 2021-09-06 |
| CA3113712A1 (en) | 2020-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4364805A3 (en) | Novel pyridazines | |
| PH12019502793A1 (en) | Aadc polynucleotides for the treatment of parkinson`s disease | |
| MX2025009223A (es) | Agentes de union a clec9a y su uso | |
| MX2020001187A (es) | Composiciones y métodos para la administración de virus adenoasociados. | |
| PH12019500204A1 (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| MX2018004755A (es) | Entrega de polinucleotidos dirigidos al sistema nervioso central. | |
| MX2018006223A (es) | Moduladores de ror-gamma. | |
| PH12021550872A1 (en) | Therapeutic compounds | |
| MX2019003363A (es) | Composiciones farmaceuticas para usarse en la terapia de la blefaritis. | |
| AU2018264384A1 (en) | Solid forms of berberine ursodeoxycholate and compositions and methods thereof | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| ZA202000375B (en) | Compounds for the prevention and treatment of medical disorders and uses thereof | |
| MY201535A (en) | Therapeutic compounds | |
| MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
| MX2020009566A (es) | Compuestos como moduladores de la se?alizacion de tlr2. | |
| MX378607B (es) | Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
| PH12021552358A1 (en) | Compounds and compositions as modulators of tlr signaling | |
| PH12021550903A1 (en) | Novel pyridazines | |
| MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
| PH12019500535A1 (en) | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | |
| MX2019014272A (es) | Compuestos policiclicos y usos de los mismos. | |
| ZA201906153B (en) | Pharmaceutical compositions for combination therapy | |
| PH12017501694B1 (en) | Compositions for the treatment of fibrosis and fibrosis-related diseases | |
| PH12018500682A1 (en) | Oxa-diazaspiro compounds having activity against pain | |
| PH12017501693A1 (en) | Compositions for the treatment of kidney and/or liver diseases |